
|Articles|July 1, 2007
- Volume 0 0
MYLAN SCORES VICTORY IN PATENT BATTLE
Advertisement
The latest round in the legal battle over the marketing of generic omeprazole delayedrelease capsules has been won by Mylan Laboratories Inc. A district court in New York ruled that Mylan's generic version of Prilosec does not infringe on AstraZeneca's patents for the popular heartburn drug. At the same time, however, the court held that generic omeprazole products made by 2 other companies, Canada's Apotex Inc and Impax Laboratories Inc in California, do infringe on AstraZeneca's patents.
Articles in this issue
about 19 years ago
pharmacy TECHNOLOGY newsabout 19 years ago
pharmacy TECHNOLOGY productsabout 19 years ago
health-systems PRODUCT newsabout 19 years ago
generic times product newsabout 19 years ago
can you READ these Rxs?about 19 years ago
A closer look at new FDA actionsabout 19 years ago
can you READ these Rxs?about 19 years ago
compounding HOTLINEabout 19 years ago
Is There Science in Quality?about 19 years ago
Vaccines: Are You Protected?Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Testing categories in practice — clinical conversations
2
FDA Grants Accelerated Approval to Iberdomide Combination for Multiple Myeloma
3
COVID-19 Variant Surveillance: A Primer for Pharmacists Navigating Vaccine Questions
4
The Vaccine Schedule Just Changed Again—Here’s What's Real and What Isn't
5






































































































